Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

RSS icon
Royal Philips has received U.S. Food and Drug Administration (FDA) approval for its new 160-cm LumiGuide endovascular navigation wire, which uses the company’s popular Fiber Optic RealShape (FORS) technology to deliver real-time 3D visualization without the use of fluoroscopy.

FDA approves longer LumiGuide 3D navigation wire from Philips

The newly approved device comes in at 160 cm. Like the shorter LumiGuide device from Philips, it was designed to deliver real-time 3D visualization with light instead of X-rays. 

money business cash flow dollar

Merit Medical to purchase Cook Medical’s lead management portfolio for $210M

Two medical device companies have announced a transaction that could shake up the U.S. electrophysiology market. 

IVUS Intravascular Ultrasound ACC

Intravascular imaging during PCI: Should cardiologists choose IVUS or OCT?

Which modality should care teams choose for PCI guidance? While there's an argument to be made for choosing IVUS over OCT, some specialists think the two treatment options are close to equal in terms of patient outcomes. 

Shockwave Medical, a Johnson & Johnson MedTech company, has officially launched its Shockwave E8 Peripheral IVL Catheter in the United States. Shockwave’s E8 catheter was designed specifically to treat patients with calcified femoropopliteal and below-the-knee (BTK) peripheral artery disease (PAD), including those diagnosed with complex chronic limb-threatening ischemia (CLTI).

Shockwave Medical launches new FDA-approved IVL catheter for PAD, CLTI

The new device, already cleared by the FDA, was designed to treat femoropopliteal and below-the-knee PAD. 

SpectraWAVE, a Massachusetts-based imaging company focused on treatments for patients with coronary artery disease (CAD), has closed a $50 million funding round. Johnson & Johnson Innovation led the round, and other participants included S3 Ventures, Lumira Ventures, SV Health Investors, Deerfield Management, NovaVenture and Heartwork Capital.

SpectraWAVE raises $50M for FDA-cleared intravascular imaging technology

The funds, including a significant investment from Johnson & Johnson, are expected to go toward expanding access to the company's HyperVue Imaging System and exploring new features.

A demonstration of SenitAR's augmented reality (AR) technology for electrophysiology lab procedures during the Heart Rhythm Society 2024 meeting. This is one of at least six FDA-cleared clinical AR and virtual reality applications that aimed at enhancing cardiology workflow and patient outcomes. Photo by Dave Fornell

A glimpse into the future: FDA has cleared multiple AR, VR tools for cardiology

Heart teams already have access to several augmented reality and virtual reality offerings, and many more are on the way.

Implantable Barostim device improves long-term heart failure symptoms

The FDA-approved device helps regulate the heart, kidneys and vascular system by targeting sensors in a patient's carotid artery. 

Abbott has received approval from the U.S. Food and Drug Administration (FDA) for its TriClip transcatheter edge-to-edge repair (TEER) system designed to treat tricuspid regurgitation (TR).

TRILUMINATE update: TEER with Abbott’s TriClip device still safe, effective after 3 years

Treatment with TriClip has been consistently associated with minimal adverse events and significant improvements in quality of life. This latest update represents data from nearly 100 patients three years after implantation.  

Displaying 41 - 48 of 2681

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Design by Adaptive Theme
Trimed Popup
Trimed Popup